Cogent Biosciences announced plans to launch bezuclastinib for Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) in the second half of 2026, supported by positive Phase 3 trial data. The company ended Q1 2026 with $866.4 million in cash, enough to fund operations through 2028. Research and development expenses rose due to pipeline advancements, while net loss increased to $97.4 million. Upcoming milestones include NDA submissions, clinical trial presentations, and new drug development programs.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
AT&T's baby bonds currently offer a 6.7% yield and trade at a 20% discount to par value due to elevated interest rates. The company reported solid Q2 results with $31.6 billion in revenue and $5.04 billion in net profit, ensuring strong coverage for ...
Michael Saylor shared a bitcoin acquisition chart for Strategy Inc., which holds 843,775 BTC worth about $54.36 billion and maintains a $3.225 billion cash reserve. The company recently raised $263.5 million by selling stock but did not buy more bitc...
Arthur Hayes, co-founder of BitMEX, purchased 1,290 ETH worth about $2.5 million, adding to growing interest in Ethereum as it consolidates below the critical $1,900 resistance level. Analysts are watching closely to see if ETH can break above $1,900...
Betterware received a reiterated 'Buy' rating with a two-year price target of $24.70–$25.60, implying about 48% upside plus a 7% dividend yield. The integration of Tupperware has significantly improved the company's earnings, increasing pro forma EPS...
